

国内版

国际版



Dual targeting PLK1 and BIRC5 in TP53-mutated hepat



ALL

IMAGES

VIDEOS

12,300 Results

Any time ▾

OCT4 increases BIRC5 and CCND1 expression and promotes ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583731>

Background. Recurrence and metastasis of **hepatocellular carcinoma** (HCC) depend on the persistent proliferative activity of **cancer** cells. **BIRC5**, also called Survivin, has been shown to play a pivotal role in cancers by influencing cell division and proliferation and by inhibiting apoptosis []. Many studies using clinical specimens have shown that **BIRC5** is invariably overexpressed in a ...

Cited by: 32

Author: Lu Cao, Chunguang Li, Shuwen Shen, Y...

Publish Year: 2013

PLK1, A Potential Target for Cancer Therapy - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S1936523316301371>

Polo-like kinase 1 (**PLK1**) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of **PLK1** may promote cancerous transformation and drive its progression. **PLK1** overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of **PLK1** could lead to death of **cancer** ...

Cited by: 81

Author: Zhixian Liu, Qingrong Sun, Xiaosheng ...

Publish Year: 2017

PLK1/NF- κ B feedforward circuit antagonizes the mono-ADP ...

<https://www.nature.com/articles/s41388-020-1205-8>

Feb 14, 2020 · Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, et al. **Dual targeting** of WEE1 and **PLK1** by AZD1775 elicits single agent cellular anticancer activity. *Acs Chem Biol.* 2017;12:1883 ...

Author: Lantian Tian, Lantian Tian, Ke Yao, K... **Publish Year:** 2020

Plk1-targeted therapies in TP53- or RAS-mutated cancer ...

<https://www.researchgate.net/publication/260806631> Plk1-



Dual targeting Polo-like kinase 1 and baculoviral inhibitor of apopto



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

9,120 Results Any time ▾

[\[PDF\] Targeting polo-like kinase 1, a regulator of p53, in ...](https://www.researchgate.net/publication/290219417...)

<https://www.researchgate.net/publication/290219417...>

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.pdf
Bussey et al. Clin Trans Med (2016) 5:1 DOI 10.1186/s40169-015-0080-3

332 - Gene ResultBIRC5 baculoviral IAP repeat containing 5 ...

<https://www.ncbi.nlm.nih.gov/gene/332>

Jul 05, 2020 · This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain.

PLK1 inhibition in cancer therapy: potentials and ...

<https://www.future-science.com/doi/full/10.4155/fmc-2019-0084>

Jul 12, 2019 · Background. The last few decades have witnessed an evolving interest in polo-like kinase 1 (PLK1) inhibitors as anticancer drugs [1]. Such interest was warranted by the overexpression of PLK1 in a broad range of cancers and its association with the poor prognosis of cancer, as well as the improved safety profile of PLK1 inhibitors versus classic mitotic inhibitors [2,3].

Cited by: 1 Author: Inas Elsayed, Xiaosheng Wang

Publish Year: 2019

Polo-like kinase 1, a new therapeutic target in ...

https://www.researchgate.net/publication/229554675_Polo-like_kinase_1_a_new...

To investigate the role of polo-like kinase 1 (PLK1) as a therapeutic target for hepatocellular carcinoma (HCC), PLK1 gene expression was evaluated in HCC tissue and HCC cell lines.

Polo-like kinase (Plk)1 depletion induces apoptosis in ...

<https://www.researchgate.net/publication/10772233...>

Depletion of the protein encoded by the polo-like kinase 1 gene (PLK1) inhibits cancer cell proliferation and induces apoptosis; therefore, it is a target for cancer therapy [33]. In this case ...

IJMS | Free Full-Text | Molecular Targeting of the ...

25-Jul-2020 06:30PM 5736 words • 11 matches • 10 sources FA2

iThenticate 56608-Review-check.docx Quotes Excluded 4% Bibliography Excluded

Name of Journal: *World Journal of Gastroenterology*
Manuscript NO: 56608
Manuscript Type: ORIGINAL ARTICLE

Basic Study
Dual targeting PLK1 and BIRC5 in TP53-mutated hepatocellular carcinoma

Li Y *et al.* Dual targeting PLK1/ BIRC5 in TP53-mutated HCC

Yan Li, Zhen-Gang Zhao, Yin Luo, Hao Cui, Hao-Yu Wang, Yan-Fang Jia, Ying-Tang Gao

Abstract
BACKGROUND
 Hepatocellular carcinoma (HCC), often diagnosed at advanced stages without curative therapies, is the fifth most common malignant cancer and the second leading cause of cancer-related mortality. Polo-like kinase 1 (PLK1) is activated in late G2 phase and is required for entry to mitosis. Interestingly, PLK1 is

Match Overview Match 1 of 1

1	Internet 26 words crawled on 09-Jul-2020 lessera.spandios-publications.com	1%
2	Internet 21 words crawled on 06-Mar-2020 www.mdpi.com	<1%
3	Internet 20 words crawled on 09-May-2020 www.ejgnet.com	<1%
4	Internet 15 words crawled on 15-Feb-2020 republishing.blob.core.windows.net	<1%
5	Internet 14 words crawled on 06-May-2019 online.library.wiley.com	<1%
6	Crossref 13 words Jonathan K. Mitchell, Bentley R. Mickitt, Benjamin Israelo w, Matthew J. Evans et al. "Hepatitis C Virus Indirectly D...	<1%
7	Internet 13 words crawled on 16-Jul-2016 spandios-publications.com	<1%
8	Internet 13 words crawled on 21-May-2020 scholarship.org	<1%
9	Crossref 12 words Julia Alejandra Pezok, Maria Sol Brasseur, Priscilla Maria Manzi Ramos, Carlos Alberto Scidell, Luiz Gonzaga Ton	<1%
	Crossref 12 words	<1%

PAGE: 1 OF 21 Text-Only Report

国内版 国际版



Dual targeting Polo-like kinase 1 and baculoviral inhibitor of apopt



ALL

IMAGES

VIDEOS

9,110 Results

Any time ▾

Polo-like kinase 1, a new therapeutic target in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400854>

Jul 21, 2012 · AIM: To investigate the role of **polo-like kinase 1** (PLK1) as a therapeutic target for **hepatocellular carcinoma** (HCC). METHODS: PLK1 gene expression was evaluated in HCC tissue and HCC cell lines. Gene knockdown with short-interfering RNA (siRNA) was used to study PLK1 gene and protein expression using real-time reverse transcription polymerase chain reaction (RT ...

Cited by: 14

Author: Wei Chuen Mok, Shanthi Wasser, There...

Publish Year: 2012

miRNA-125a-5p inhibits hepatocellular carcinoma cell ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601372>

Keywords: **hepatocellular carcinoma**, microRNA-125a-5p, TP53-regulated **inhibitor of apoptosis 1**, B cell lymphoma-2-like 2 protein, **apoptosis**, migration Introduction **Hepatocellular carcinoma** (HCC) is the sixth most common cancer worldwide, and is associated with almost half a million cases of mortality every year (1).

Cited by: 4

Author: Ma Ming, Ma Ying, Ma Ling

Publish Year: 2019

(PDF) Targeting polo-like kinase 1, a regulator of p53, in ...

https://www.researchgate.net/publication/290219417_Targeting_polo-like_kinase_1_a...

Targeting **polo-like kinase 1**, a regulator of p53, in the treatment of adrenocortical **carcinoma**.pdf
Bussey et al. Clin Trans Med (2016) 5:1 DOI 10.1186/s40169-015-0080-3

PLK1 inhibition in cancer therapy: potentials and ...

<https://www.future-science.com/doi/full/10.4155/fmc-2019-0084>

Jul 12, 2019 · Background. The last few decades have witnessed an evolving interest in **polo-like kinase 1** (PLK1) **inhibitors** as anticancer drugs [].Such interest was warranted by the overexpression of PLK1 in a broad range of cancers and its association with the poor prognosis of